Introduction {#Sec1}
============

Multidrug-resistance (MDR) among Gram-negative pathogens is an urgent public health threat as bacteria continue to create new modes of resistance to evade the current mainstays of antimicrobial therapy \[[@CR1], [@CR2]\]. The evolution of β-lactam resistance among Enterobacteriaceae, *Pseudomonas aeruginosa*, and *Acinetobacter*spp., has forced clinicians to resort to antimicrobial agents that have poorly defined pharmacokinetic/pharmacodynamic (PK/PD) targets, as well as significant toxicity which limit their reliability in infection eradication \[[@CR1], [@CR3]\]. Plazomicin (formerly ACHN-490), a neoglycoside, has demonstrated activity against Gram-negative bacteria expressing a wide range of resistance mechanisms \[[@CR4]\]. Aminoglycosides (AGs) are broad spectrum, bactericidal, antibiotics used for treating complicated urinary tract infections (cUTIs), nosocomial respiratory tract infections, and septicemia. Similar to other classes of antibiotics, resistance to AGs has emerged with up to 30% of Enterobacteriaceae demonstrating resistance to gentamicin, tobramycin, and/or amikacin \[[@CR5], [@CR6]\]. The limited availability of antibiotics to treat serious MDR infections attests to the need for novel agents such as plazomicin.

Data sources {#Sec2}
============

Literature searches were conducted using the MEDLINE (1963--May 2018) and EMBASE (1988--May 2018) databases, searching using the terms "ACHN-490", "aminoglycosides", and "plazomicin". English articles were used to obtain results, and additional citations were gained through information provided from literature specific to plazomicin. Current Trials, in addition to information outlined in FDA review documents, were also reviewed. Finally, data presented within this article was collected from conference proceedings; including published abstracts.

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Chemistry and mechanism of action {#Sec3}
=================================

AGs act primarily by impairing bacterial protein synthesis through binding to the A-site of the 16S ribosomal RNA (rRNA); functionally known as the decoding center of the 30s ribosome \[[@CR7], [@CR8]\]. The passage of these highly polar molecules across the outer membrane of Gram--negative bacteria is an energy-dependent process involving the drug-induced disruption of Mg^2+^ bridges between adjacent lipopolysaccharide molecules. The unique combination in the uptake of AGs, as well as the inhibition of bacterial protein synthesis, aid in producing the concentration-dependent killing exhibited by this class of antimicrobials \[[@CR9]--[@CR11]\].

AG resistance develops through several mechanisms that can coexist simultaneously within the same isolate. Mechanisms of resistance include modification of the AG target site through the mutation of the 16S rRNA or ribosomal proteins, methylation of 16S rRNA, reduced permeability by modification of the outer membrane, or the enzymatic inactivation of the antibiotic molecule through the development of AG-specific transferases. For Enterobacteriaceae, resistance to AGs is caused primarily by AG modifying enzymes (AMEs) \[[@CR9]\]. AMEs are defined by various transferases including those that inactivate AGs by *N*-acetylation \[AG acetyltransferase (AAC)\], *O*-adenylation \[AG-nucleotidyltransferase (ANT)\], or *O*-phosphorylation \[AG-phosphotransferases (APH)\]. These enzymes can be present in the transferable elements or chromosomes of the bacteria. Transferases are diverse with respect to the positions of the AG scaffold that they attack, as well as the genes that encode them \[[@CR5], [@CR10]\].

Synthesized through an eight-step process, plazomicin (C~25~H~48~N~6~O~10~) (Fig. [1](#Fig1){ref-type="fig"}), was derived utilizing the original chemistry of sisomicin (C~19~H~37~N~5~O~7~). The construction of plazomicin was consummated through the basic rendering of sis sulfate followed by a subsequent reaction with ethyl trifluorothioacetate to selectively form the 6′trifluoroacetamide. Comparable to sisomicin, which excludes the 3′-and 4′--OH groups characterized in the traditional AG pharmacophore, plazomicin is active against the APH (3′) and ANT (4′) enzymes. Contrary to its parent compound, the extension in plazomicin's spectrum of activity is exhibited through the institution of a hydroxyamino butyric acid (HABA) substituent at position 1 and a hydroxyethyl substituent at position 6′. The aforementioned modification at the 1′ position provides additional protection from the AAC (3), ANT (2″), and APH (2″) AMEs, while the addition of the hydroxyethyl group at the 6′ position supplements further protection from the AAC (6′) AME, present in various Enterobacteriaceae (see Fig. [1](#Fig1){ref-type="fig"}) \[[@CR11]\].Fig. 1Structure of plazomicin and modification sites. The hydroxyamino butyric acid (HABA) substituent (green dotted line) at position 1 and the hydroxyethyl compound addition at the 6′-N position, enhancing plazomicin's activity against various aminoglycoside-modifying enzymes. The 2′-N position remains unblocked to AACs

Represented in Fig. [1](#Fig1){ref-type="fig"} is plazomicin derived from its parent molecule, sisomicin. Distinct differences between the two molecules are represented through the presence of the two side chains located on plazomicin's C1 and C6′ nitrogen atoms. Plazomicin is protected from the APH (3′) and ANT(2″) AMEs through the lack in hydroxyl groups at positions C3′ and C4′, and consequently inactivity to the AAC (2′) AME is preserved \[[@CR7]--[@CR11]\].

Microbiology {#Sec4}
============

The in vitro activity of plazomicin and comparator AGs against various Gram-negative and Gram-positive pathogens, several of which are characterized by AMEs and extended spectrum beta-lactamases **(**ESBLs), are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. The minimum inhibitory concentration (MIC~50~ and MIC~90~, range) values are representative of pooled data from studies conducted with plazomicin. Preference was given to those studies conducted using isolates collected within the last 3 years when summarizing these data. Standard MIC determination methods were conducted under neutral pH conditions in accordance with Clinical and Laboratory Standard Institute procedures \[[@CR11]--[@CR16]\].Table 1In vitro activities of plazomicin and comparators against resistant isolates \[[@CR11]--[@CR16]\]SpeciesAGMIC50 (mg/L)MIC90 (mg/L)MIC rangeAll EnterobacteriaceaePlazomicin0.510.25 to 8AMK^a^8641 to \> 64GEN^b^32 \> 640.5 to \> 64TOB^c^32 \> 320.5 to \> 32*Escherichia coli*Plazomicin0.510.5 to 4AMK \< 8 \> 32 \< 8 to 32GEN8 \> 8 \< 2 to 8TOB32 \> 321 to 32*Enterobacter*spp.Plazomicin0.51 \< 0.5 to 16AMK864 \< 1 to \> 64GEN32 \> 64 \< 1 to \> 64TOB0.5640.5 to 64*Klebsiella pneumoniae*Plazomicin0.510.25 to 8AMK32 \> 32 \< 8 to 32GEN48 \< 2 to 8TOB32 \> 320.5 to 64*Pseudomonas aeruginosa*Plazomicin8640.5 to \> 64AMK16 \> 641 to \> 64GEN \> 64 \> 648 to \> 64TOB2160.5 to \> 64*Acinetobacter*spp.Plazomicin16321 to \> 64AMK \> 64 \> 644 to \> 64GEN \> 64 \> 642 to \> 64TOB \> 64 \> 642 to 64Methicillin-resistant *Staphylococcus aureus*Plazomicin120.25 to 4AMK16 \> 640.5 to \> 64GEN32 \> 640.25 to \> 64TOB------^a^*AMK* amikacin^b^*GEN* gentamicin^c^*TOB* tobramycin

The observed in-vitro activity of plazomicin encompasses a variety of AG-resistant organisms, such as *Staphylococcus aureus*, members of the Enterobacteriaceae family,*P. aeruginosa* and *Acinetobacter* spp., as well as AMEs and ESBLs expressed within the aforementioned organisms \[[@CR11]--[@CR15]\].

When tested against 493 methicillin-resistant *S. aureus* isolates, plazomicin exhibited superior activity against these isolates in comparison to amikacin and gentamicin \[[@CR11]\]. The MIC~50~ and MIC~90~ values for plazomicin were 1 and 2 mg/L respectively, in comparison to 32 and \> 64 mg/L for gentamicin, and 16 and \> 64 mg/L for amikacin \[[@CR11]--[@CR15]\].

Of 407 *A. baumanni* isolates gathered through a surveillance study, high rates of non-susceptibility to the three traditional AGs was observed \[[@CR11]\]. Among the isolates studied, 80%, exhibited a plazomicin MIC~50~ of ≤ 8 mg/L, while the remaining 20% displayed an MIC~50~ of ≥ 16 mg/L. High -level AG resistance (HLAR), defined as an MIC~50~ of \> 64 mg/L, was documented in 21 strains. The molecular analysis of 20 of the 21 strains with HLAR revealed AAC (3)-Ib as the most prevalent AME responsible for the observed resistance. A MIC~50~ of 8 mg/L for plazomicin was documented for 4 of the 20 strains presenting with HLAR predominately attributed to the AAC (3)-Ib AME; for the remaining 16 strains, an MIC~50~ of \> 16 mg/L was observed, similar to that of the traditional AGs \[[@CR11], [@CR16], [@CR17]\].

In *P. aeruginosa*, the activity of plazomicin was comparable to amikacin. A plazomicin MIC of 16 mg/L was found in 62% of *P. aeruginosa* isolates, while 38% or *P. aeruginosa* positive isolates displayed MICs ≥ 32 mg/L. Two isolates presented with AAC (3)-Ib, an AME possibly attributable to the documented resistance. The plazomicin MIC for these two strains harboring the AAC (3)-Ib AME was found to be \> 64 mg/L \[[@CR11], [@CR16]\]. Upregulation of efflux pumps, most commonly orchestrated through the MexXy efflux pump, compromises the antimicrobial effect of AGs. The presence of the MexXy efflux pump in *P. aeruginosa* and *Acinetobacter* spp. correlates to plazomicin's decline in activity among these organisms \[[@CR16]--[@CR18]\]. The most prevalent AG-modifying enzymes that contribute to AG resistance in Enterobacteriaceae are AAC (3)-II, AAC (6′)-I, and ANT (2″)-I \[[@CR2], [@CR3]\]. As represented in Table [2](#Tab2){ref-type="table"}, plazomicin remains highly potent against each of these AMEs \[[@CR11]--[@CR19]\].Table 2Plazomicin and comparators activity against AMEs and ESBLs \[[@CR11]--[@CR19]\]Organism groupPhenotypeMIC (mg/L)AMKGENPlazomicin*Escherichia coli*ATCC 25,992^a^211ANT(2″)-I^b^4 \> 641AAC(6′)-I^c^3240.25AAC(3)-II4 \> 642APH(3′)-Ib^d^0.50.250.25AAC(3)-Iva4321*Klebsiella pneumoniae*ATCC 10,0310.50.120.25*Providencia stuartii*AAC (2′) \> 64 \> 648*Pseudomonas aeruginosa*ATCC 27,853212Wild-type pump414ΔEfflux pumps0.50.1250.125MexXY up428ANT (4′)-II3244AAC(3)-I4648AAC(6′)-II4322*Acinetobacter*spp.APH(3′)-VI \> 6411ATCC 19,60616168AAC(6′)-I3282*Staphylococcus aureus*ATCC 29,21340.51ANT(4′)-I \> 640.51APH(3′)-III20.50.5APH(2″) + AAC(6′)64 \> 644ESBL^e^sCTX-M^f^, AmpC^g^, SHV^h^, TEM^i^1681KPCs^j^16641^a^*ATCC* American Type Culture Collection quality control strain^b^*AAC*N-Acetyltransferase catalyzes acetyl CoA-dependent acetylation of amino group^c^*ANT* O-Adenyltransferase catalyzes ATP-dependent adenylation of hydroxyl group^d^*APH*O-phosphotransferase catalyzes ATP-dependent phosphorylation of hydroxyl group^e^*ESBLs* Extended-spectrum beta lactamases produced by *E. coli*, *K. pneumoniae,* and *Enterobacter* spp.^f^*CTX-M* Class A ESBL^g^*AmpC* Class C ESBL^h^*SHV* Class B ESBL^i^*TEM* Class A ESBL^j^*KPC Klebsiella pneumoniaecarbapenamase* Class A beta-lactamase

Also represented in Table [2](#Tab2){ref-type="table"} is plazomicin's activity against common ESBLs. While ESBLs do not directly inhibit AG activity, they are frequently plasmid-encoded \[[@CR20]\]. The encoded plasmids are responsible for carrying AME genes, which prohibit AG activity \[[@CR21]\]. Nevertheless, plazomicin in vitro activity against ESBL-producing strains was retained when tested against 209 isolates in which these enzymes were present. Gentamicin's and amikacin's MICs were documented as 8 mg/L and 16 mg/L, respectively; plazomicin maintained MICs at 1 mg/L for all ESBL-producing strains \[[@CR12]--[@CR15]\]. These results indicate the improved activity of plazomicin against AMEs as well as ESBLs harboring strains that are typically resistant to AGs \[[@CR12]--[@CR21]\].

Although the data is limited, there are several in-vitro studies that have assessed the potential for combination therapy with plazomicin. Utilizing the checkerboard assay method, Thwaites et al. assessed various MDR Enterobacteriaceae with MIC values ranging from 0.5 to 8 mg/L The assay demonstrated synergy when plazomicin was used in combination with piperacillin/tazobactam, meropenem, and ceftazidime. However, for the combination of levofloxacin, tigecycline and colistin, neither synergy nor antagonism was observed with plazomicin. Time-kill analysis was performed in this study to further confirm the initial observation of synergy. The results from the time-kill analysis further demonstrated plazomicin's synergistic capabilities with a \> 3-log reduction in organisms from baseline exhibited when used in combination with both ceftazidime and piperacillin/tazobactam \[[@CR22]\].

Rodriguez-Avial et al., using checkerboard techniques, also observed synergistic activity when plazomicin was combined with meropenem, colistin, and fosfomycin against carbapenemase-producing Enterobacteriaceae. Similar to the study conducted by Thwaites et al., antagonism was not observed in any of the combinations \[[@CR23]\].

The outcomes of these studies demonstrate the potential use of plazomicin in combination with other antimicrobials in the treatment of MDR Gram-negative infections \[[@CR22], [@CR23]\].

Pharmacokinetics/Pharmacodynamics {#Sec5}
=================================

The pharmacokinetic (PK) properties of plazomicin have been evaluated through two phase 1, randomized, double-blind, placebo-controlled studies conducted in healthy human subjects.

Study 1 was a parallel-group design, with escalating single (SD) and multiple doses (MD), while the second study included patients receiving a longer duration of the highest tolerated dose from the first study. The dosing of traditional AGs (5--7 mg/kg daily) served as a reference for the dosing of plazomicin utilized in the first study. The patient cohorts in study 1 were dosed ascendingly (cohorts 1a--4),beginning with 1 mg/kg, 4 mg/kg, 7 mg/kg, 11 mg/kg, and concluding with 15 mg/kg. Patients received either a SD or MD of plazomicin, for a descending number of days (cohort 1b for 10 days, cohort 2 for 10 days, cohort 3 for 5 days, and cohort 4 for 3 days). The subjects that received plazomicin in study 2 received 15 mg/kg once daily for 5 days \[[@CR24]\].

The 28 subjects of study 1 who received the plazomicin injection were included in the SD and MD PK analyzes. The mean peak plasma plazomicin concentration was attained either at or shortly following initiation. Following the single dose administration, the mean ± standard deviation *C*~max~ ranged from 8 ± 0.8 mg/L in the 1-mg/kg group to 144 ± 45 mg/L in the 15-mg/kg group. Following the conclusion of the infusion, the decline in plazomicin concentrations appeared to be multiphasic, with a decline immediately following initiation, and then a biphasic elimination in the terminal phase; beginning at 16--24 h. The elimination half-life was measured at 12 h following the initial dosing. The mean area under the curve (AUC) ranged from 15 ± 1 h × mg h/L in the 1 mg/kg group to 246 ± 39h × mg h/L in the 15 mg/kg group. Study 1 results for AUC versus dose (mg) and *C*~max~ versus dose (mg), following the initial once-daily 10-min intravenous infusion of the plazomicin injection, were linear and dose-proportional \[[@CR24]\].

The mean plasma PK parameters for the patients that received multiple doses in cohorts 1b--4 were generally similar to that of the patients who received a single-dose for each respective cohort. Elimination half-lives were also were similar in both groups across each study, ranging from 3 to 4 h. Steady-state volumes were attained following the second dose of plazomicin, with the volume of distribution having limited variability across both studies. Similar PK parameters were observed in the patients who received 15 mg/kg MD daily versus those that received a SD daily of 15 mg/kg for both studies 1 and 2. The *C*~max~ from those patients in study 1 who received multiple doses of plazomicin was documented to be 117 ± 28 mg/L, while the *C*~max~ was 113 ± 17 mg/L for those patients who had received 15 mg/kg once-daily in study 2. The AUC~0--24~ was 224 ± 37 mg h/L, and 235 ± 44 mg h/L for the 15-mg/kg allocated group in study 1 versus study 2, respectively. In addition, these studies demonstrated that plazomicin's 20% protein binding was concentration-independent and that, following excretion, 97.5% of the drug was recovered in the urine. Although the AUC has been shown to be an important indicator in aminoglycoside efficacy, a higher *C*~max~ has been correlated with better tissue penetration which is imperative in terms of preventing adaptive antimicrobial resistance \[[@CR5], [@CR24]\].

To further confirm the targeted dose exposure PK/PD relationships, a plazomicin murine septicemia study was conducted using a dose of 28 mg/kg to simulate the 15-mg/kg once-daily dosing in humans. Using this dosing strategy an AUC of 269 mg h/L was obtained. The mice studied were infected with a variety of Enterobacteriaceae spp. exhibiting MIC values ranging from 2 to 16 mg/L. Overall, plazomicin therapy increased survival for 86% of the mice with organism MIC values of ≤ 4 mg/L and 54% for those with organisms exhibiting MICs of ≥ 8 mg/L \[[@CR25]\].

The efficacy in plazomicin's dosing strategy was additionally evaluated through a small randomized, double-blind, phase two study, comparing plazomicin 10 mg/kg, 15 mg/kg, and levofloxacin 750 mg (each administered daily). Plazomicin dosed at 15 mg/kg once-daily was shown to be an effective treatment in the adult patients diagnosed with a cUTI. The microbiological infection was eradicated in over 85% of patients who received plazomicin, with 80% of patients who received the 15 mg/kg daily dose of plazomicin being pronounced clinically cured, per the complete resolution of baseline signs and symptoms of infection. In addition, a lower rate of disease recurrence was observed in the 15-mg/kg once-daily plazomicin group in comparison to the levofloxacin group \[[@CR26]\].

These various studies demonstrate that the recommended 15-mg/kg once-daily dosing of plazomicin provides the most optimal pharmacokinetics and pharmacodynamics outcomes required to eradicate resistant organisms \[[@CR24]--[@CR26]\].

Within the phase 3 trial, "Combating Antibiotic-Resistant Enterobacteriaceae (CARE)"; the management of plazomicin through therapeutic drug monitoring (TDM) for 22 patients, noted as being critically ill, was evaluated. Renal function varied in this patient population, ranging from a creatinine clearance (CrCl) of \< 36 mL/min to 224 mL/min. Patient's received 4--14 days of plazomicin therapy, with therapeutic drug monitoring utilized in each patient to attain an AUC of 262 mg\*h/L for plazomicin. At the conclusion of therapy, two patients had CrCl that rose above baseline; however, the elevated serum creatinine did resolve within 48 h post-treatment. While the third patient experienced renal decline, the investigators were able to attribute this matter to septic shock unrelated to the plazomicin therapy \[[@CR27]\]. In an additional study evaluating plazomicin, Komirenko et al. compared groups with varying renal function, normal to severe (CrCl \> 90 ml/min, CrCl \< 15 ml/min r,espectively). Plazomicin was administered as a single dose of 7.5 mg/kg to six individuals of four renal function groups (normal, mild, moderate, and severe) and the collection of PK samples took place on days 1--5. The variation of Cmax across each group was not severely impacted by a decline in renal function (37.9 ± 5.01, 32.8 ± 4.30, 39.2 ± 6.43, and 41.4 ± 7.83, respectively to each group); however, the AUC~0--24~, as well as the total clearance, did show an inversely proportional relationship to the decline in renal function. An approximate fivefold increase in plazomicin AUC levels was exhibited in the severe renal impairment group in relation to the normal renal function group (647 ± 259 mg h/L and 136 ± 17.2 mg h/L, respectively); while the total clearance time, indicated in L/h, decreased nearly fivefold in the severely renally impaired group when compared to the individuals with a normal Crcl (0.96 ± 0.379 L/h and 4.64 ± 1.17 L/h, respectively) \[[@CR28]\].

These results demonstrate that for patients with comprised renal function the modification of plazomicin dosing, including the application of therapeutic drug monitoring, would be recommended in providing optimal bacterial eradication while protecting the patient from kidney injury via elevated drug exposure \[[@CR27], [@CR28]\].

Resistance {#Sec6}
==========

In-vitro studies indicate that the development of resistance to plazomicin is similar to that of the traditional aminoglycosides. The development of plazomicin resistance was evaluated in an in vitro chemostat model, in which exposure to plazomicin was applied to 10 isolates (equal numbers in the *E. coli* and *K. pneumoniae* groups) in increasing concentrations. Resistant isolates in this study were defined as those that had with a fourfold increase in MIC readings post-baseline, following a baseline MIC reading of 4. In the strains that developed resistance, per the study definition, an AUC of 66 mg h/L was identified. This AUC is far below the AUC achieved with the recommended 15-mg/kg once-daily dosing; increasing the risk of the development in common AG resistance mechanisms. Resistance was not detected in those isolates for which an AUC of \> 66 mg h/L was observed. Despite plazomicin's success in evading most mechanisms of aminoglycoside resistance, the presence of the New Delhi metallo-β-lactamases (NDM), in strains of *E. coli* and *K. pneumoniae* did render the drug ineffective. Due to the encoded plasmids of NDM being avid producers of 16S rRNA methylases, the plazomicin-associated MICs were \> 8 mg/L; indicating resistance to this metallo-β-lactamase \[[@CR29]\].

Drug--drug interactions {#Sec7}
=======================

The likelihood of drug--drug interactions with plazomicin was determined following the in vitro testing of plazomicin against a panel of drug-metabolizing enzymes as well as drug transporters. Due to plazomicin being 97.5% excreted, unchanged, through the urine, the interaction with drug enzymes is unlikely. Interactions with major drug transporters, such as the p-glycoprotein, was also not observed in plazomicin trials \[[@CR24]--[@CR28]\].

Clinical efficacy {#Sec8}
=================

At this time, plazomicin has been evaluated for the treatment of cUTI including acute pyelonephritis (AP) in one Phase II and one Phase III clinical study \[[@CR30]\]. A small, pathogen-specific Phase III trial in patients with carbapenem-resistant Enterobacteriaceae (CRE) bacteremia or hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) was also recently completed (Table [3](#Tab3){ref-type="table"}**)** \[[@CR30], [@CR31]\].Table 3Clinical studiesConnolly et al. \[[@CR26], [@CR30]\]EPIC \[[@CR32], [@CR33]\]CARE \[[@CR27], [@CR31]\]DesignPhase II, randomized, double-blindPhase III, randomized, multi-centered, double-blindCohort 1\
Phase III, pathogen-specific, randomized, multi-centered, open-labelCohort 2\
Phase III, pathogen-specific, single armPatientsAdults with cUTI/AP\
*n* = 92^a^Adults with cUTI/AP\
*n* = 388^b^Adults with CRE bacteremia or HAPBP/VAPBP and APACHE II ≥ 15\
*n* = 37^b^Adults with CRE bacteremia, HAPBP/VAPBP or cUTI not eligible for cohort 1\
*n* = 27InterventionPlazomicin 10 mg/kg/day vs. plazomicin 15 mg/kg/day vs. levofloxacin 750 mg/day × 5 daysPlazomicin 15 mg/kg/day vs. meropenem 1 g q8h\
Optional switch to oral therapy after 4 days study drugPlazomicin 15mg/kg/day vs. colistinPlazomicin 1 5mg/kg/dayPrimary outcome(s)Microbiological eradication at TOC:^c^\
Treatment difference plazomicin 15 mg/kg/day -- levofloxacin MITT 2.2% (95% CI − 22.9%, 27.2%)\
ME 7.6% (95% CI − 16%, 31.3%)Clinical + microbiological cure at day 5: treatment difference plazomicin -- meropenem, 3.4% (95% CI −10.0%, 3.1%) TOC: 11.6% (95% CI 2.7%, 20.3%)^d^28-day all-cause mortality or significant infection-related complications: plazomicin 4 (23%) vs. colistin 10 (50%) (one-sided *P* = 0.058)28-day all-cause mortality 6 (22.2%)*APACHE* Acute Physiology and Chronic Health Evaluation,*CI* confidence interval,*CRE* carbapenem-resistant Enterobacteriaceae,*cUTI* complicated urinary tract infection,*HABP* hospital-acquired bacterial pneumonia,*ME* microbiologically evaluable,*MITT* modified intention-to-treat,*mMITT* microbiologic modified intention-to-treatm,*TOC* test of cure,*VABP* ventilator-associated bacterial pneumonia^a^Modified intention-to-treat-population^b^Microbiologic modified intention-to-treat-population^c^5--12 days after last treatment^d^Days 15--19

The Phase III cUTI/AP study (EPIC) was a randomized, multicenter, multinational, double-blind trial evaluating the safety and efficacy of once-daily plazomicin (15 mg/kg) versus meropenem (1 g, every 8 h) in adults with cUTI/AP \[[@CR32], [@CR33]\]. Patients could be switched to oral levofloxacin (or alternative in the case of resistance) following 4 days of IV therapy for a total treatment duration of 7--10 days. Key exclusion criteria included severe renal impairment (CrCl ≤ 30 mL/min), body weight \> 150 kg, and urine pathogen resistant to meropenem. A total of 609 patients were randomized, of whom 388 received at least one dose of any study drug and had at least one qualifying pathogen on the baseline urine culture (microbiological modified intention-to-treat population, mMITT). All Enterobacteriaceae were considered to be qualifying pathogens, while *P. aeruginosa* and *Acinetobacter* spp. were not \[[@CR32], [@CR33]\].

Baseline demographic and clinical characteristics were generally well balanced between study arms. The mean age was 59.4 years, and slightly over half (52.8%) were female. Most patients (98.5%) were enrolled from Eastern Europe and were predominantly Caucasian (99.5%). The mean CrCl was approximately 75 mL/min, with 34.0% of patients having a CrCl of 30--60 mL/min. Overall, 27.5% and 26.0% of patients were infected with ESBL-producing and aminoglycoside-resistant pathogens, respectively. CRE was isolated from the baseline urine culture in 15 (3.9%) patients \[[@CR29], [@CR30]\]. The MIC~50/90~ for plazomicin against Enterobacteriaceae were 0.5/1 mg/L. Among ESBL-producing and aminoglycoside-resistant Enterobacteriaceae, the plazomicin MIC~50/90~ were 0.25/0.5 mg/L and 0.25/2 mg/L, respectively. Blood cultures were positive in 48 (12.4%) patients \[[@CR32]\].

Plazomicin demonstrated non-inferiority to meropenem for the co-primary efficacy endpoints of composite clinical and microbiological cure at day 5 (treatment difference plazomicin--meropenem − 3.4%, 95% CI − 10.0, 3.1) and the test-of--cure time point (TOC, day 17 ± 2) (difference 11.6--15%, 95% CI 2.7, 20.3) \[[@CR31], [@CR32]\]. The difference favoring the plazomicin arm at the TOC time point was driven by a fairly large decrease in microbiological eradication in the meropenem arm (microbiological eradication day 5, 98.4% vs. 98.0%, TOC 89.0% vs. 74.6%, plazomicin vs. meropenem, respectively). Microbiological eradication favoring the plazomicin arm was sustained through to the late follow-up visit (LFU, day 24--32) (84.3% vs. 65.0%) \[[@CR31], [@CR32]\]. The reason behind this precipitous decline in the meropenem microbiological eradication rates is unclear, although this pattern was also recently observed in the meropenem--vaborbactam cUTI trial where the composite cure rate dropped over 20% from the end-of-therapy to the TOC visit in both β-lactam arms, again driven by microbiological failure \[[@CR32], [@CR33]\]. It is possible that plazomicin may have a benefit for sustained microbiological eradication due to PK properties such as the post-antibiotic effect and achievement of high urine concentrations. Although the clinical relevance of these findings is not clear, it is notable that, at the LFU visit (days 24--32), clinical relapse was also higher in the meropenem group (1.6% vs. 7.1%) \[[@CR33]\].

Efficacy outcomes in subgroups were generally consistent with the main analysis. Microbiological eradication rates tended to favor plazomicin among all Enterobacteriaceae and specifically in ESBL-producing and aminoglycoside-resistant strains \[[@CR33]\].

Although the results of this study support the use of plazomicin as an effective carbapenem-sparing alternative for cUTI, several limitations affect the generalizability of the findings. First, the vast majority of the patients were Caucasian and therefore not representative of countries such as the US which have a more diverse racial makeup. Next, due to concerns from non-clinical studies about plazomicin's activity against *P. aeruginosa* and *Acinetobacter* spp., these pathogens were excluded from the mMITT analysis. Although not common causes of cUTI, in clinical scenarios where they are likely pathogens, an alternative agent may be preferred until more clinical data are available. Finally, patients with severe renal impairment were excluded. As elderly patients with age-related declines in renal function make up a large proportion of patients with cUTI, more data about the safety and efficacy of plazomicin in these patients are needed.

In addition to the EPIC study, an earlier Phase II, multicenter, randomized, double-blind study evaluated the efficacy, safety, and PK of two doses of plazomicin (10 mg/kg and 15 mg/kg) compared to levofloxacin for the treatment of cUTI/AP \[[@CR26], [@CR30]\]. As a Phase II study, no formal hypothesis testing was conducted and the overall sample size was relatively small (*n* = 145). However, this study does provide important data pertaining to a possible plazomicin dose--response relationship as well as on the use of plazomicin in a cohort of patients who differed considerably from the Phase III study by demographic characteristics. In this study, the majority of patients (53.8%) were enrolled from North American sites, the racial distribution was more diverse (37.2% American Indian or Alaska Native, 29.7% Asian and 15.2% African American), the mean age was only 42.6 years and 80.0% were female (ITT population) \[[@CR31], [@CR33]\]. There did appear to be a trend toward higher microbiological eradication at the TOC time point in the 15 mg/kg arm (plazomicin 10 mg/kg: 6/12 50% vs. 15 mg/kg: 31/51 60.8% vs. levofloxacin: 17/29 58.6%), although the number of indeterminate results (5, 15, and 8, respectively) and the small, imbalanced sample sizes do make the results difficult from which to draw conclusions \[[@CR31], [@CR33]\].

Finally, the CARE study was a Phase III pathogen-specific, multicenter, randomized, open-label trial evaluating plazomicin versus colistin (plus background therapy with meropenem or tigecycline) for CRE bacteremia or HABP/VABP. A parallel single arm cohort (cohort 2) included patients treated with plazomicin for bacteremia, HABP/VABP who were not eligible for primary analysis and patients treated with plazomicin monotherapy for cUTI. Key exclusion criteria for the main analysis (cohort 1) included polymicrobial infection, APACHE II score \< 15 and known colistin-resistant infection. The original planned sample size was for over 350 patients including 286 in the mMITT population. However, due to enrollment difficulties (2100 patients screened but less than 2% met inclusion criteria and were included in the trial) the study was stopped after 37 patients had been enrolled in the mMITT population (17 plazomicin and 20 colistin). With regards to demographic characteristics, most patients (59.5%) were at least 65 years of age and 67.6% were enrolled from Greece. Nearly half (45.9%) of patients had an APACHE II score above 20. Although balance was achieved between groups with regards to pre-specified stratification criteria (i.e., infection type, APACHE II score, and time from initial empiric therapy to randomization), due to the small sample size, there were disparities in important demographic characteristics such as age, gender, study site and background therapy. The majority of patients (78.4%) were in the bacteremia stratum. More than half of bacteremic patients had an intravascular central catheter at the time of diagnosis. All patients in the HABP/VABP stratum had VABP and none had positive blood cultures. Carbapenem-resistant *K. pneumoniae* was the qualifying pathogen in 36/37 patients, while carbapenem-resistant *Enterobacter aerogenes* was isolated from the blood culture of a single patient in the plazomicin group. Prior antibiotics were used for up to 72 h before enrollment in almost all of the patients, most commonly colistin or meropenem \[[@CR27], [@CR31]\].

The primary endpoint was a composite of 28-day all-cause mortality or significant disease-related complications \[new/worsening acute respiratory distress syndrome, new lung abscess within 7 days, worsening septic shock within 7 days, new CRE bacteremia within 7 days or persistent ( ≥ 7 days) CRE bacteremia\]. A total of 10 (50%) and 4 (23.4%) of patients in the colistin and plazomicin arms experienced the primary outcome, respectively (one-sided *P* = 0.094). Eight (40%) and two (11.8%) experienced 28-day mortality, respectively (one-sided *P* = 0.058). Numerical trends favored plazomicin for the primary outcome in all subgroups, particularly in the analysis restricted to bacteremic patients (8/15, 53.3% vs. 2/14, 14.3%; one-sided *P* = 0.033). Only one patient with bacteremia assigned to plazomicin experienced 28-day mortality. It should be noted, however, that 6 and 5 patients in the colistin and plazomicin arms, respectively, had negative blood cultures within 24 h prior to initiation of the study drug.

A total of 27 patients were enrolled in cohort 2: 14 patients with bacteremia, 9 with HABP/VABP and 4 with cUTI. All patients were enrolled in Greece and all had carbapenem-resistant *K. pneumoniae* as the qualifying pathogen. There was a total of six (22.2%) deaths in the cohort and all occurred in patients with either bacteremia (2/14) or HABP/VABP (4/9) \[[@CR31], [@CR32]\].

Although the results from the CARE study were numerically favorable for plazomicin, the efficacy analysis was limited by several factors. Most significantly, the sample size of cohort 1 consisted of only 37 patients. As such, the results were presented descriptively without the use of inferential statistics. Furthermore, the small sample size led to substantial uncertainty regarding the precise values of the treatment effects. Despite randomization, important differences in baseline characteristics were present. Finally, cohort 2 lacked a control group and patients were not comparable enough to the plazomicin group of cohort 1 to allow a synthesized analysis \[[@CR31]\].

On May 3, 2018, the US FDA Antimicrobial Drugs Advisory Committee voted unanimously that the evidence supported the cUTI/AP indication but voted 4--11 (yes--no) that results from the CARE study did not provide "substantial evidence of safety and effectiveness of plazomicin for the treatment of bloodstream infection in patients with limited or no treatment options." The US FDA subsequently follow suit by approving the cUTI/AP indication but rejecting the bacteremia indication \[[@CR33]\].

Safety {#Sec9}
======

To date, the safety of plazomicin has been evaluated in 612 subjects who received varying doses in six phase 1, one phase 2, and two phase 3 studies. This safety database identifies signals for anticipated risks of an aminoglycoside, including nephrotoxicity and ototoxicity, and more general side effects such as headache, nausea and vomiting.

In the phase 2 and phase 3 cUTI/AP studies, nephrotoxicity (defined as an increase in serum creatinine ≥ 0.5 mg/dL) were identified more frequently in the plazomicin arms than in the comparator arms (5.6% vs. 2.4% and 7.0% vs. 4.0%, respectively). Serum creatinine increases ≥ 1 mg/dL were infrequent: 9 (3%) plazomicin treated patients and 3 (1.0%) of meropenem patients in the phase 3 cUTI/AP study. Two patients in each treatment arm of the phase 3 cUTI/AP study experienced acute kidney failure.

As with other AGs, plazomicin-associated nephrotoxicity is significantly associated with increased trough levels (*C*~min~). Pooled PK data from the two cUTI/AP studies also revealed that the incidence of plazomicin-induced nephrotoxicity was higher in patients with baseline CrCl 30--60 mL/min versus \> 60 mL/min, even at comparable *C*~min~. The incidence of nephrotoxicity at different *C*~min~ thresholds stratified by CrCl is outlined in Table [4](#Tab4){ref-type="table"}.Table 4Incidence of nephrotoxicity by baseline creatinine clearance and plazomicin trough levelPlazomicin trough^a^ (mg/L)Nephrotoxicity^b^n/N (%)CrCl \> 60 mL/min.^c^CrCl 30--60 mL/min.^c^ ≥ 0.59/148 (6)13/100 (13) ≥ 1.06/88 (7)12/78 (15) ≥ 1.54/53 (8)10/56 (18) ≥ 2.04/30 (13)10/46 (22) ≥ 2.53/18 (17)8/31 (26) ≥ 3.03/13 (23)7/19 (37)*CrCl* creatinine clearance^a^Day 1 trough level; data pooled from PK population of phase 1 and 2 cUTI/AP studies^b^Serum creatinine increase ≥ 0.5 mg/L while on plazomicin or during follow-up^c^Estimated using the Cockcroft--Gault Equation

Classification and regression tree analysis of these data identified C~min~ of 3 mg/L and CrCl around 60 mL/min as critical thresholds associated with a higher incidence of nephrotoxicity. On the other hand, nephrotoxicity did not appear to be associated with duration of treatment (up to 7 days) or concomitant nephrotoxic medications.

In the CARE study, plazomicin doses were adjusted to target an AUC~0--24h~ range of 200--400 mg h/L, corresponding to 75% and 150% of the mean AUC~0--24h~ (262 mg h/L) in cUTI patients with normal renal function. Overall, 86.2% of patients in the study required dosage adjustment to stay within range and a mean of 1.9 adjustments per patient. Among patients in the CARE study with baseline and post-baseline serum creatinine measurements, there were fewer patients with serum creatinine increases ≥ 0.5 mg/L in the plazomicin compared to the colistin arm (2/12, 16.7% vs. 8/16, 50.0%). No patients in the plazomicin arm experienced a serum creatinine increase ≥ 1 mg/L versus 7/16 (43.8%) in the colistin arm. Based on data from this study, the t arget AUC~0--24h~ range was subsequently modified to 210--315 mg h/L.

Assuming an approximately linear relationship between *C*~min~ and AUC~0--24h~ and the exposure--response relationship for nephrotoxicity observed in the cUTI/AP studies, the FDA projected the upper bound of the target range corresponds to *C*~min~ values of 5.7 mg/L and 8.7 mg/L (AUC~0--24h~ 315 and 400 mg h/L, respectively), which would be expected to be associated with high rates of nephrotoxicity. Additionally, PK/PD targets for net bacterial stasis derived from a neutropenic thigh model and plazomicin MIC values for Enterobacteriaceae suggests that the lower bound exceeds the AUC~0--24h~ required to attain PK/PD values several-fold. As a result, therapeutic drug monitoring to maintain *C*~min~ \< 3 mg/L is recommended for all patients with a CrCl 15--90 mL/min, rather than dosing guided by AUC~0--24h.~

Plazomicin's ototoxic potential was evaluated using pure tone audiometry in Phase 1 and 2 studies. An independent expert review of these data concluded there was no widespread signal for drug-induced ototoxicity. Similarly, no clear signal of vestibulotoxicity was found following review of electronystagmography, modified Romberg testing and dynamic visual acuity testing results performed in Phase 1 and 2 studies. Due to the practical impediments limiting the use of typical measures such as audiometric tests or Romberg testing in hospitalized patients, evaluation of plazomicin's ototoxic potential in the cUTI/AP studies was primarily based on the use of several validated inventories related to patient-perceived changes in hearing, tinnitus, and dizziness as well as patient-reported adverse events. Hyperacusis, tinnitus, and vertigo were reported by three patients. Whereas aminoglycoside-related ototoxicity is typically non-reversible and bilateral in nature, these events were somewhat atypical in that the hyperacusis and vertigo resolved and the tinnitus was unilateral. The clinical safety data parallel the results of animal models suggesting that at equivalent doses plazomicin had a lower ototoxic potential than both gentamicin and amikacin \[[@CR34]\].

Conclusion {#Sec10}
==========

With the increasing prevalence of MDR Gram--negative organisms, there has been a resurgence in the use AGs, particularly in combination regimens \[[@CR5]--[@CR9]\]. Plazomicin retains AG concentration-dependent bactericidal activity, while evading common AMEs \[[@CR6]\]. The prolonged antibiotic effect and structural modifications enhance plazomicin's action against Gram--negative pathogens that render broad-spectrum antibiotics defenseless \[[@CR5]--[@CR11]\].

The variety of data presented supports the observed clinical cure and microbiological eradication demonstrated in plazomicin trials, attesting to its recent FDA approval in the treatment of MDR Enterobacteriaceae cUTIs, including acute pyelonephritis \[[@CR30]\]. Despite the limited population of patients included in the CARE study evaluating the utility of plazomicin against CRE, a potential therapeutic role for plazomicin was suggested through the decline of mortality in those patients treated with plazomicin as salvage therapy \[[@CR27]\]. In-vitro testing has shown that plazomicin is active against the most prevalent of AMEs, including those carried by ESBL-producing pathogens \[[@CR11]--[@CR20]\]. Plazomicin could have the potential to be used a narrower-spectrum alternative to broad-spectrum beta-lactams, specifically carbapenems. Use of plazomicin in these settings may reduce selective pressure attributing to the development of beta-lactam resistance \[[@CR21]\]. It would also be interesting to learn whether plazomicin's narrower spectrum translates into a lower risk of *Clostridium difficile* infections. The promising results of synergy experiments suggest a potential role for plazomicin in combination regimens. The combinations exhibited synergy and were successful in overcoming the heteroresistance to broad-spectrum beta-lactams traditionally observed in the Enterobacteriaceae species \[[@CR22], [@CR23]\].

The recommended dosing profile, 15 mg/kg once-daily, attributes to plazomicin's possible role in therapy, as it may be a convenient option for outpatient therapy in patients with Enterobacteriaceae infections requiring an extended duration of antimicrobial treatment \[[@CR24]\].

Nevertheless, the safety profile of plazomicin is consistent with that of the traditional aminoglycosides; indicating the need for plazomicin dose adjustment through using a lower targeted dose of 10 mg/kg once- daily or the integration of TDM in individuals with comprised renal function \[[@CR27], [@CR28]\]. The observed toxicities associated with plazomicin include nephrotoxicity and ototoxicity, both documented in lesser amounts than that of the other systemically available AGs, although relatively few patients have been exposed to plazomicin at this point \[[@CR34]\].

Based upon the attested spectrum of activity profile, as well as an established PK/PD profile validated by clinical studies, plazomicin has the ability to serve as an efficacious therapy for treating MDR Enterobacteriaceae infections.
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